US OptionsDetailed Quotes
RCUS241220P10000
- 0.39
- 0.000.00%
15min DelayClose Nov 29 13:00 ET
0.00High0.00Low
0.39Open0.39Pre Close0 Volume12 Open Interest10.00Strike Price0.00Turnover181.17%IV37.76%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.39Extrinsic Value100Contract SizeAmericanOptions Type-0.1048Delta0.0282Gamma39.59Leverage Ratio-0.0300Theta-0.0010Rho-4.15Eff Leverage0.0065Vega
Arcus Biosciences Stock Discussion
Sign in to post a comment
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
16
3
See Biotech companies with cancer assets 👇
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
10
1
The recent sale of Arcus Biosciences shares by the COO and the lack of insider buying over the last year raises caution. The level of insider ownership indicates some alignment between management and smaller shareholders, but it's not particularly high.
1
Despite a moderate P/S ratio, the company's revenue growth lags behind others, potentially problematic if the trend persists. Muted future growth estimates compared to the industry could lead to disappointment if the P/S aligns with the growth outlook.
Arcus Biosciences' cash runway is promising despite a significant drop in revenue. However, shareholders may face costly dilution if the company sells shares to cover another year's operations. The falling revenue is concerning for the cash burning company.
Despite the weaker earnings outlook, the consensus price target suggests analysts do not anticipate a long-term impact on the company’s valuation. However, the downgrade of next year's forecast instills caution regarding Arcus Biosciences' future performance.
Arcus Biosciences' falling revenue is concerning despite its reassuring cash runway. Though the forecast of reaching breakeven soon is positive, the potential for share dilution due to further cash raising is a risk for shareholders.
$Arcus Biosciences (RCUS.US)$Revenue surged in the past two years, reaching 0.38 billion in 2021, operating profit turned around in 2021 to 0.054 billion, and net income reached 0.053 billion.
Revenue grew 1.8 times in the first three quarters of 2022 to 0.08 billion, operating profit losses narrowed to 0.21 billion, net income losses narrowed to 0.2 billion. The full-year profit depends entirely on the performance of the fourth quarter, making it difficult to evaluate its investment value at this time.
Revenue grew 1.8 times in the first three quarters of 2022 to 0.08 billion, operating profit losses narrowed to 0.21 billion, net income losses narrowed to 0.2 billion. The full-year profit depends entirely on the performance of the fourth quarter, making it difficult to evaluate its investment value at this time.
Translated
Gainers:
In reaction to earnings/guidance:
• $GoodRx (GDRX.US)$ +38.5%, $EDGIO (EGIO.US)$ +13.5%, $Lemonade (LMND.US)$ +10.7%, $Desktop Metal (DM.US)$ +8.5%, $ShockWave Medical (SWAV.US)$ +8.2%, $Pubmatic (PUBM.US)$ +8.1%, $Olaplex (OLPX.US)$ +7%, $Vivid Seats (SEAT.US)$ +6.4%, $Noble (NE.US)$ +6.3%, $Aspen Technology (AZPN.US)$ +5.4%, $AAON Inc (AAON.US)$ +5%, $Hudbay Minerals (HBM.US)$ +5%, $Vivint Smart Home (VVNT.US)$ +4.9%, $Vivint Smart Home (VVNT.US)$ +4...
In reaction to earnings/guidance:
• $GoodRx (GDRX.US)$ +38.5%, $EDGIO (EGIO.US)$ +13.5%, $Lemonade (LMND.US)$ +10.7%, $Desktop Metal (DM.US)$ +8.5%, $ShockWave Medical (SWAV.US)$ +8.2%, $Pubmatic (PUBM.US)$ +8.1%, $Olaplex (OLPX.US)$ +7%, $Vivid Seats (SEAT.US)$ +6.4%, $Noble (NE.US)$ +6.3%, $Aspen Technology (AZPN.US)$ +5.4%, $AAON Inc (AAON.US)$ +5%, $Hudbay Minerals (HBM.US)$ +5%, $Vivint Smart Home (VVNT.US)$ +4.9%, $Vivint Smart Home (VVNT.US)$ +4...
24
Gainers:
• $Arcus Biosciences (RCUS.US)$ +11.2% (appointed to join S&P SmallCap 600)
• $Sphere 3d (ANY.US)$ +10.13% (mutually agreed to terminate merger agreement with Gryphon Digital Mining)
• $Theravance Biopharma (TBPH.US)$ +3.05% (announced results from Study 0170)
• $Carnival (CUK.US)$ +4.7% (reported that March 28-April 3 was the busiest booking week in company history)
• $Castle Biosciences (CSTL.US)$ +4.4% (agreed to acquire Althe...
• $Arcus Biosciences (RCUS.US)$ +11.2% (appointed to join S&P SmallCap 600)
• $Sphere 3d (ANY.US)$ +10.13% (mutually agreed to terminate merger agreement with Gryphon Digital Mining)
• $Theravance Biopharma (TBPH.US)$ +3.05% (announced results from Study 0170)
• $Carnival (CUK.US)$ +4.7% (reported that March 28-April 3 was the busiest booking week in company history)
• $Castle Biosciences (CSTL.US)$ +4.4% (agreed to acquire Althe...
12
No comment yet
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long